Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $83 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
- Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
- Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
- Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)